Sunzen Group Berhad (“Sunzen” or “the Group”), formerly known as Sunzen Biotech Berhad and an established player in Malaysia’s health products, medical devices and services, and loan financing with a diversified portfolio, today announced its unaudited financial results for the second quarter ended 31 December 2025 (“Q2 FY2026”), recording revenue of RM30.24 million and profit before tax (“PBT”) of RM6.65 million. The strong performance was underpinned by improved export sales of edible bird’s nest, robust growth in loan financing income, and successful recovery of previously impaired receivables.
For the current quarter, revenue rose 10.6% year-on-year from RM27.35 million in the corresponding quarter last year, driven mainly by higher export volumes of edible bird’s nest and stronger financing income. PBT surged 130.0% to RM6.65 million compared to RM2.89 million previously, reflecting higher product margins and effective credit recovery efforts.
Quarter-on-quarter (“QoQ”), revenue increased sharply by 53.7% from RM19.68 million in the preceding quarter, while PBT improved 80.2% from RM3.69 million. The sequential improvement was largely attributable to seasonal peak exports of edible bird’s nest and food and beverage products, alongside stronger financing contribution.
For the cumulative six months ended 31 December 2025 (“6M FY2026”), the Group recorded revenue of RM49.92 million, broadly stable compared to RM50.31 million in the previous corresponding period. Despite marginally softer top-line performance year-to-date (“YTD”), PBT climbed significantly by 175.7% to RM10.34 million from RM3.75 million, supported by improved product margins and the successful recoupment of previously impaired receivables.
The Human Health segment remained the Group’s largest contributor, registering revenue of RM22.77 million in Q2 FY2026, up 8.6% from RM20.96 million a year ago, driven by stronger export sales of edible bird’s nest. Quarterly PBT more than doubled to RM1.40 million from RM0.69 million, reflecting margin improvement. On a YTD basis, the segment turned profitable with PBT of RM1.00 million compared to a loss of RM0.21 million previously, signalling a meaningful operational turnaround despite softer average selling prices in the China market earlier in the financial period.
The Medical Devices and Services segment recorded revenue of RM2.65 million for the quarter, an 8.6% increase year-on-year. PBT rose 61.0% to RM0.66 million, supported by improved margins. For the six-month period, revenue reached RM4.64 million while PBT stood at RM0.90 million, reflecting growing traction from its ophthalmic product offerings and clinical support services. It should be noted that the comparative period in the preceding year reflected only a three-month contribution, following the completion of the acquisition of the business in October 2024.
The Loan Financing segment continued to demonstrate strong growth momentum, with quarterly revenue rising 51.4% year-on-year to RM4.83 million. PBT increased 63.6% to RM3.78 million, driven by higher interest income and improved debt recovery. On a YTD basis, revenue expanded 46.6% to RM9.47 million while PBT climbed 53.8% to RM7.23 million, reinforcing the segment’s position as a key earnings anchor for the Group.
Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming said, “This quarter marks a significant improvement in our earnings profile, driven by stronger export momentum in edible bird’s nest and sustained growth in our financing division. The successful recovery of receivables has further strengthened our bottom line. Our diversified earnings base continues to provide resilience. While seasonality remains a factor in certain segments, we are focused on strengthening distribution channels, enhancing operational efficiency, and building recurring income streams to support long-term profitability.”
Looking ahead, the Group expects its Human Health segment to continue expanding its distribution footprint, including deeper engagement with chain retailers and broader participation in fast-moving consumer goods channels to mitigate seasonality. Online sales channels are expected to remain a supportive growth driver, while demand for bird’s nest exports to China is anticipated to normalise in line with seasonal trends. The Medical Devices and Services segment may experience temporary moderation in medical devices orders during festive periods due to fewer elective procedures, although long-term demand fundamentals remain intact.
Meanwhile, sustained demand for SME financing is expected to continue supporting the Loan Financing segment’s growth trajectory, providing revenue visibility and recurring income stability for the Group. With strengthened profitability, disciplined cost management, and a diversified income base, Sunzen remains cautiously optimistic about maintaining earnings momentum in the coming quarters.
